Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
82 hedge funds and large institutions have $24.7M invested in Lumos Pharma, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 16 closing their positions.
27% more capital invested
Capital invested by funds: $19.5M → $24.7M (+$5.2M)
6% less funds holding
Funds holding: 87 → 82 (-5)
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
67% less call options, than puts
Call options by funds: $28K | Put options by funds: $84K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.09M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$407K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$373K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$199K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.13M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$429K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$204K |
| 4 |
Morgan Stanley
New York
|
-$175K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$99.1K |
LUMO Hedge Fund Activity: Q1 2019 in Review
82 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2019, worth a combined $24.7M — up 27% from $19.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LUMO and 12 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 20 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.09M. The largest seller was JP Morgan Chase, cutting an estimated $1.13M.
- 82 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2019, down from 87 in Q4 2018.
- Funds reported $24.7M of Lumos Pharma, Inc. Common Stock stock for Q1 2019, up 27% quarter-over-quarter.
- 12 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2019 and 16 closed out, a net change of -4 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2019 was Renaissance Technologies, an estimated $1.09M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q1 2019 was JP Morgan Chase, an estimated $1.13M sold.
Based on aggregated 13F filings for Q1 2019.